Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,309,831
  • Shares Outstanding, K 45,300
  • Annual Sales, $ 1,686 M
  • Annual Income, $ 475,800 K
  • 60-Month Beta 0.64
  • Price/Sales 4.87
  • Price/Cash Flow 15.54
  • Price/Book 1.97
Trade UTHR with:

Options Overview Details

View History
  • Implied Volatility 44.33% ( -0.96%)
  • Historical Volatility 30.85%
  • IV Percentile 91%
  • IV Rank 49.24%
  • IV High 62.13% on 10/15/21
  • IV Low 27.07% on 01/31/22
  • Put/Call Vol Ratio 0.08
  • Today's Volume 13
  • Volume Avg (30-Day) 363
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 12,306
  • Open Int (30-Day) 10,162

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 3.81
  • Number of Estimates 5
  • High Estimate 4.35
  • Low Estimate 3.42
  • Prior Year 3.65
  • Growth Rate Est. (year over year) +4.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
173.21 +5.90%
on 04/27/22
195.07 -5.96%
on 04/22/22
-6.75 (-3.55%)
since 04/13/22
3-Month
158.38 +15.82%
on 03/11/22
206.97 -11.37%
on 02/15/22
-20.13 (-9.89%)
since 02/11/22
52-Week
158.38 +15.82%
on 03/11/22
218.38 -16.00%
on 12/31/21
-10.33 (-5.33%)
since 05/13/21

Most Recent Stories

More News
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up

United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

LLY : 291.63 (-0.06%)
UTHR : 183.44 (+1.14%)
XNCR : 23.95 (+0.67%)
PRPH : 7.03 (+7.82%)
5 Undervalued Stocks to Scoop Up in May

The market selloff caused by the difficult macroeconomic and geopolitical issues has led many quality stocks to now trade below their intrinsic values. Agilent Technologies (A), United Therapeutics (UTHR),...

A : 119.38 (+2.80%)
BHC : 10.84 (+3.73%)
NSANY : 7.6696 (+0.26%)
UTHR : 183.44 (+1.14%)
WIRE : 127.41 (+2.19%)
United Therapeutics (UTHR) Q1 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 69.93% and 12.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

UTHR : 183.44 (+1.14%)
BBI : 0.1863 (-9.96%)
United Therapeutics Corporation Reports First Quarter 2022 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew...

UTHR : 183.44 (+1.14%)
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that eight posters and three mini-symposia across the company’s commercial and development portfolio will...

UTHR : 183.44 (+1.14%)
United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings Growth

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UTHR : 183.44 (+1.14%)
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2022 financial results before the market opens on Wednesday, May 4, 2022.

UTHR : 183.44 (+1.14%)
UnitedHealth (UNH) to Post Q1 Earnings: What to Expect

UnitedHealth Group's (UNH) first-quarter results are likely to reflect the benefits of improving premiums and products.

UNH : 485.40 (+1.38%)
UTHR : 183.44 (+1.14%)
CARA : 8.40 (+10.38%)
CLOV : 2.61 (+13.97%)
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso...

UTHR : 183.44 (+1.14%)
MNKD : 3.01 (+10.26%)
3D Systems Stock Giving Bargain Opportunities

3D printing and digital manufacturing solutions provider 3D Systems (NASDAQ: DDD) stock has sold-off over (-60%) from its pandemic high of $56.50.

UTHR : 183.44 (+1.14%)
DDD : 10.36 (+7.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability....

See More

Key Turning Points

3rd Resistance Point 188.59
2nd Resistance Point 186.80
1st Resistance Point 185.12
Last Price 183.44
1st Support Level 181.65
2nd Support Level 179.86
3rd Support Level 178.18

See More

52-Week High 218.38
Fibonacci 61.8% 195.46
Fibonacci 50% 188.38
Last Price 183.44
Fibonacci 38.2% 181.30
52-Week Low 158.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar